These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 17197802)

  • 1. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline HIV RNA and the when to start question: time to stop asking this question?
    Mussini C
    AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
    AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies of HIV management--when to start.
    Youle M
    AIDS; 2002; 16 Suppl 4():S145-9. PubMed ID: 12699011
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 9. Stopping antiretroviral therapy in 'prematurely treated' HIV-1-infected children with full viral supression is safe.
    Reula ES; León-Leal JA; Leal M; Obando I; Muñoz-Fernández A
    AIDS; 2006 Jan; 20(2):307-9. PubMed ID: 16511434
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV treatment interruptions: a review.
    Newcomb-Fernandez J
    Res Initiat Treat Action; 2003; 9(2):5-13. PubMed ID: 14989199
    [No Abstract]   [Full Text] [Related]  

  • 16. CD4 cell count-guided treatment interruption: be smart and wait for more evidence.
    Arduino R
    Clin Infect Dis; 2005 Mar; 40(5):735-7. PubMed ID: 15714421
    [No Abstract]   [Full Text] [Related]  

  • 17. Trying to make sense of treatment interruptions.
    Lewis D; Sutton RE
    Res Initiat Treat Action; 2003; 9(2):14-5. PubMed ID: 14989200
    [No Abstract]   [Full Text] [Related]  

  • 18. When to start, when to STI (or, groping for the golden moment).
    Mascolini M
    IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
    [No Abstract]   [Full Text] [Related]  

  • 19. [The current status of structured treatment interruption].
    Nakata H; Mitsuya H
    Nihon Rinsho; 2002 Apr; 60(4):807-12. PubMed ID: 11968793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.